Company attributes
Other attributes
Incyte is a global biopharmaceutical company, founded in 2002 in Wilmington, Delaware, by a team of research scientists, chemists and biologists working in immunology. The company has grown to employ over 1400 people and has operations in the U.S., Europe, and Japan. Incyte focuses on the discovery and development of small-molecule drugs.
The company has a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. They are advancing a growing pipeline of medicines across two franchises: Oncology and Inflammation & Autoimmunity.
Clinical trials are testing the viability of Incyte drugs for the treatment of coronavirus. As of February 2020, Camrelizumab (humanized monoclonal antibody targeting PD-1) and thymosin are being used in two ongoing clinical trials.
